Results 31 to 40 of about 80,404 (95)

Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis: post-marketing surveillance study

open access: yesBMC Gastroenterology
Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We aimed to identify the safety and effectiveness of tofacitinib in patients with UC in routine clinical settings in Korea.
Hyuk Yoon   +7 more
doaj   +1 more source

Systematic Review of Global Practices and Challenges in Pre- and Post-Marketing Surveillance of Polyherbal Formulations

open access: yesFuture Natural Products
Background and aims: Polyherbal preparations have emerged as promising solutions for various diseases and conditions globally, owing to their combined benefits derived from multiple herbal plants.
Senarathne Mudiyanselage Ruwini Nishadini Senarathne   +2 more
doaj   +1 more source

The clinical effectiveness of tafluprost on Japanese normal-tension glaucoma patients

open access: yesClinical Ophthalmology, 2018
Akio Nomura,1 Hirotaka Osaki,1 Fumiki Shimada,1 Yasuaki Kuwayama2 1Pharmacovigilance, Quality Compliance Division, Santen Pharmaceutical Co., Ltd., Osaka, Japan; 2Fukushima Eye Clinic, Osaka, Japan Purpose: This study evaluates the effect of tafluprost
Nomura A, Osaki H, Shimada F, Kuwayama Y
doaj  

Assessment of safety and efficacy of lamotrigine over the course of 1-year observation in Japanese patients with bipolar disorder: post-marketing surveillance study report

open access: yesNeuropsychiatric Disease and Treatment, 2017
Takeshi Terao,1 Atsuko Ishida,2 Toshifumi Kimura,3 Mitsuhiro Yoshida,4 Terufumi Hara2 1Department of Neuropsychiatry, Faculty of Medicine, Oita University, Oita, 2Post-Marketing Surveillance Department, 3MA Specialty & General Care Medicine ...
Terao T   +4 more
doaj  

Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study

open access: yesDrugs - Real World Outcomes, 2019
Background To understand the extent to which a large-scale healthcare claims database (DB) captures the safety profile of eribulin mesylate (Halaven®, Eisai Co., Ltd., Japan), we compared patient characteristics, drug use, and adverse events (AEs ...
Yukinori Sakata   +5 more
doaj   +1 more source

A retrospective pharmacovigilance study of post-marketing safety concerns with cefuroxime

open access: yesTherapeutic Advances in Drug Safety
Background: Cefuroxime has played a crucial role in the prevention and treatment of bacterial infections. However, the differences in adverse events across formulations and routes remain unclear.
Cheng Jiang   +4 more
doaj   +1 more source

The application of digitization and digital marketing for the recovery of Ukraine's economy

open access: yesВісник Харківського національного університету імені В.Н. Каразіна: Серія Економіка
The article explores the potential application of digital technologies and digital marketing for the post-war recovery of Ukraine's economy. The war in Ukraine has led to significant destruction and economic losses, making it crucial to explore pathways ...
N. Nazarenko, A. Nochovka
doaj   +1 more source

Post-marketing safety concerns with rimegepant based on a pharmacovigilance study

open access: yesThe Journal of Headache and Pain
Purpose This study aimed to comprehensively assess the safety of rimegepant administration in real-world clinical settings. Methods Data from the Food and Drug Administration Adverse Event Reporting System (FAERS) spanning the second quarter of 2020 ...
Jia-Ling Hu   +5 more
doaj   +1 more source

Active Surveillance of Adverse Events Following Influenza Immunization in Jiangsu Province, China: A 2019–2023 Retrospective Study

open access: yesVaccines
Background: Influenza vaccines have been administered in Jiangsu Province. This study aimed to conduct a comprehensive retrospective analysis of influenza vaccine safety in the region from 2019 to 2023.
Zhiguo Wang   +7 more
doaj   +1 more source

Interim analysis of all-case post-marketing surveillance study in Japan: lecanemab in patients with early Alzheimer’s disease

open access: yesThe Journal of Prevention of Alzheimer's Disease
Background: Lecanemab is a monoclonal antibody targeting amyloid-beta protofibrils, indicated for patients with mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease.
Atsushi Iwata   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy